Evidence map›Paper›PMID 19077215›Full record

ArticleRetrovirology2008

Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.

Wayne B Dyer, John J Zaunders, Fang Fang Yuan, Bin Wang, Jennifer C Learmont, Andrew F Geczy, Nitin K Saksena, Dale A McPhee, Paul R Gorry, John S Sullivan

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Transcriptional insights into the CD8Journal of translational medicine · 2020
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Naïve CD4BMC immunology · 2021
    Article
  14. CD8Frontiers in microbiology · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Possible clearance of transfusion-acquiredJournal of virus eradication · 2019
    Article
  19. Article
  20. Identification of miRNA-mRNA crosstalk in CD4Journal of translational medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Wayne B DyerAustralian Red Cross Blood Service, 153 Clarence Street, Sydney, NSW 2000, Australia. wdyer@arcbs.redcross.org.au
John J Zaunders
Fang Fang Yuan
Bin Wang
Jennifer C Learmont
Andrew F Geczy
Nitin K Saksena
Dale A McPhee
Paul R Gorry
John S Sullivan
Australian Red Cross Lifeblood · AUUniversity of Sydney · AUMonash University · AUSt. Vincent's Birmingham · USSt Vincents Institute of Medical Research · AUWestmead Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElite non-progressors (plasma viral load < 50 copies/ml while antiretroviral naive) constitute a tiny fraction of HIV-infected individuals. After 12 years follow-up of a cohort of 13 long-term non-progressors (LTNP) identified from 135 individuals with transfusion-acquired HIV infection, 5 remained LTNP after 23 to 26 years infection, but only 3 retained elite LTNP status. We examined the mechanisms that differentiated delayed progressors from LTNP in this cohort.

resultsA survival advantage was conferred on 12 of 13 subjects, who had at least one host genetic factor (HLA, chemokine receptor or TLR polymorphisms) or viral attenuating factor (defective nef) associated with slow progression. However, antiviral immune responses differentiated the course of disease into and beyond the second decade of infection. A stable p24-specific proliferative response was associated with control of viraemia and retention of non-progressor status, but this p24 response was absent or declined in viraemic subjects. Strong Gag-dominant cytotoxic T lymphocyte (CTL) responses were identified in most LTNP, or Pol dominant-CTL in those with nef-defective HIV infection. CTL were associated with control of viraemia when combined with p24 proliferative responses. However, CTL did not prevent late disease progression. Individuals with sustained viral suppression had CTL recognising numerous Gag epitopes, while strong but restricted responses to one or two immunodominant epitopes was effective for some time, but failed to contain viraemia over the course of this study. Viral escape mutants at a HLA B27-restricted Gag-p24 epitope were detected in only 1 of 3 individuals, whereas declining or negative p24 proliferative responses occurred in all 3 concurrent with an increase in viraemia.

conclusionDetectable viraemia at study entry was predictive of loss of LTNP status and/or disease progression in 6 of 8, and differentiated slow progressors from elite LTNP who retained potent virological control. Sustained immunological suppression of viraemia was independently associated with preserved p24 proliferative responses, regardless of the strength and breadth of the CTL response. A decline in this protective p24 response preceded or correlated with loss of non-progressor status and/or signs of disease progression.

Indexed as

HIV Long-Term SurvivorsTransfusion ReactionAmino Acid SequenceCD4-Positive T-LymphocytesCohort StudiesDisease ProgressionGene Products, gagHIV-1HIV Core Protein p24HIV InfectionsHumansLymphocyte ActivationRNA, ViralViral LoadViremiaGene Products, gagHIV Core Protein p24p24 protein, Human Immunodeficiency Virus Type 1RNA, Viral

Identifiers

PMID19077215
PMCPMC2633348
OpenAlexW2040900515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.